Published in Cancer on August 01, 1988
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC) | NCT00866957
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
Hepatocellular carcinoma. Postgrad Med J (2000) 1.67
Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer (2012) 1.47
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19
Hepatocellular carcinoma: is current therapy really altering outcome? Gut (2002) 1.16
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol (1992) 1.15
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer (2006) 1.11
Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol (2012) 1.10
Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol (2007) 1.07
Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res (2008) 1.04
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs (2008) 1.04
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer (2004) 1.00
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol (2016) 0.97
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer (1989) 0.95
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics (2008) 0.95
Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol (2014) 0.92
Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res (2011) 0.92
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. J Gastroenterol (2006) 0.90
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer (2005) 0.89
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist (2014) 0.89
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer (2001) 0.88
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer (2003) 0.87
Models of hepatocellular carcinoma and biomarker strategy. Cancers (Basel) (2010) 0.86
Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal (2013) 0.86
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol (2015) 0.84
Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. Acta Biomater (2013) 0.84
A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs (2007) 0.82
MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int (2013) 0.82
Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol (2015) 0.82
Hepatocellular carcinoma--rising incidence, changing therapeutic strategies. Wien Med Wochenschr (2006) 0.82
Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology (2012) 0.81
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.81
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol (2012) 0.80
Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study. J Med Device (2014) 0.80
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Systemic therapy in hepatocellular carcinoma. Clin Liver Dis (2011) 0.78
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. World J Gastroenterol (2007) 0.78
Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era. Cancer Res Treat (2010) 0.77
Update on new approaches in the management of hepatocellular carcinoma. Hepat Med (2010) 0.77
Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Intern Med (1996) 0.77
The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy. Semin Intervent Radiol (2006) 0.76
Interventional radiological treatment of hepatocellular carcinoma: an update. Indian J Surg (2011) 0.76
Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol (2013) 0.76
Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. J Cancer Res Clin Oncol (2015) 0.76
Liver disease. Postgrad Med J (1994) 0.76
Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies. Medicine (Baltimore) (2016) 0.75
Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selected patients? World J Surg Oncol (2013) 0.75
Patterns of presentation, referral, and treatment of hepatocellular carcinoma in a pre-sorafenib era: experience of a Canadian provincial cancer agency. Curr Oncol (2011) 0.75
Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis. Mol Clin Oncol (2014) 0.75
Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS One (2017) 0.75
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75
Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol (2017) 0.75
Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol (2017) 0.75
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases (2015) 0.75
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol (1996) 4.81
Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology (1987) 3.65
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice. Neuron (2000) 2.73
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 2.72
Characteristics of patients with benign gastric outlet obstruction requiring surgery after endoscopic balloon dilation. Am J Gastroenterol (1996) 2.63
Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet (2001) 2.55
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene (2001) 2.25
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology (1998) 2.19
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. J Clin Microbiol (1993) 1.85
Correlation of Pectolytic Enzyme Activity with the Programmed Release of Cells from Root Caps of Pea (Pisum sativum). Plant Physiol (1990) 1.84
Variants of the adenomatoid odontogenic tumor with a note on tumor origin. J Oral Pathol Med (1992) 1.84
Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology (1999) 1.80
Clear cell carcinoma of liver. An ultrastructural study. Cancer (1983) 1.72
The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron (1990) 1.72
Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat (2001) 1.70
Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology (2000) 1.69
Phosphorylation and inhibition of olfactory adenylyl cyclase by CaM kinase II in Neurons: a mechanism for attenuation of olfactory signals. Neuron (1998) 1.63
Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology (1993) 1.63
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology (1997) 1.62
Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics (2000) 1.55
On the denaturation of deoxyribonucleic acid. II. Effects of concentration. Biochim Biophys Acta (1967) 1.51
Studies on the loss and the restoration of the transforming activity of the deoxyribonucleic acid of Bacillus subtilis. Biochim Biophys Acta (1967) 1.48
Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol (1997) 1.48
Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome. Cancer (1993) 1.47
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res (2000) 1.46
Hepatitis C virus infection in kidney transplant recipients. Hepatology (1993) 1.46
Functional mutation in the promoter region of thrombomodulin gene in relation to carotid atherosclerosis. Atherosclerosis (2001) 1.45
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology (1992) 1.44
Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children. Pediatr Nephrol (1992) 1.44
Histologic prognostic indicators in hepatocellular carcinoma. Cancer (1979) 1.43
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Synergism of chronic alcoholism and hepatitis B infection in liver disease. J Gastroenterol Hepatol (1991) 1.40
Granulocytic sarcoma presenting as bleeding gastric polyp. Pathology (1989) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Images in cardiovascular medicine: infantile Marfan's syndrome. Circulation (1998) 1.38
Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol (2000) 1.37
Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med (1981) 1.34
Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.34
Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology (1987) 1.33
CNS stem and progenitor cell differentiation into functional neuronal circuits in three-dimensional collagen gels. Exp Neurol (2004) 1.33
Molecular basis of beta thalassemia in south China. Strategy for DNA analysis. Hum Genet (1988) 1.32
Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology (1990) 1.31
Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr (2001) 1.30
Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy. Circulation (1992) 1.29
Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology (1988) 1.28
Inflammatory pseudotumour of the mouth and maxilla. J Clin Pathol (1996) 1.28
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 1.27
Occult hepatitis B virus infection: a hidden menace? Hepatology (2001) 1.26
High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology (1996) 1.25
Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol (1987) 1.24
Microscopic origin of the giant ferroelectric polarization in tetragonal-like BiFeO(3). Phys Rev Lett (2011) 1.24
Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology (2001) 1.22
Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet (1987) 1.20
Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci (1991) 1.20
Hepatic veno-occlusive disease due to toxic alkaloid herbal tea. Lancet (1983) 1.20
Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer (1981) 1.19
The conditional survival statistics for survivors with primary supratentorial astrocytic tumors. J Neurooncol (2000) 1.19
In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm (2001) 1.19
Activation of the human beta-globin promoter in K562 cells by DNA sequences 5' to the fetal gamma- or embryonic zeta-globin genes. J Clin Invest (1987) 1.19
Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci (1987) 1.18
Cell division of Escherichia coli: control by membrane organization. J Bacteriol (1973) 1.18
Ovarian sex cord tumor with annular tubules: a report of six cases. Gynecol Oncol (1993) 1.16
Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer (2001) 1.16
Desmoplastic variant of ameloblastoma in Chinese patients. Br J Oral Maxillofac Surg (1998) 1.15
Hepatitis B infection in patients with lymphomas. Hematol Oncol (1991) 1.12
Osteochondroma of the coronoid process of the mandible. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol (1993) 1.12
Current seroepidemiology of hepatitis A in Hong Kong. J Med Virol (1991) 1.12
On the denaturation of deoxyribonucleic acid. Biochim Biophys Acta (1966) 1.11
The upstream region of the human gamma-globin gene promoter. Identification and functional analysis of nuclear protein binding sites. J Biol Chem (1991) 1.11
Naturally occurring hepatitis B virus core gene mutations. Hepatology (1995) 1.10
Does a "false negative" MIBG scan predict a better outcome in neuroblastoma patients? Med Pediatr Oncol (2001) 1.10
Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat (1999) 1.10
An autopsy study of hepatocellular carcinoma in Hong Kong. Pathology (1981) 1.09
Enhanced hippocampal CA1 LTP but normal spatial learning in inositol 1,4,5-trisphosphate 3-kinase(A)-deficient mice. Learn Mem (1999) 1.09
The heterogeneity in risk factors of lung cancer and the difference of histologic distribution between genders in Taiwan. Cancer Causes Control (2001) 1.09
Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med (1989) 1.09
Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet (1988) 1.08
Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood (2001) 1.07
En bloc resection for extensive hepatocellular carcinoma: is it advisable? World J Surg (1995) 1.07
The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis (1998) 1.07
Ewing sarcoma of the small intestine. J Pediatr Hematol Oncol (2001) 1.06
A survey of tumours of the jawbones in Hong Kong Chinese: 1963-1982. Br J Oral Maxillofac Surg (1985) 1.06
Frequency-domain fluorescence microscopy with the LED as a light source. J Microsc (2001) 1.05